Letter: Levodopa in dystonia.
作者信息
Eldridge R, Kanter W, Koerber T
出版信息
Lancet. 1973 Nov 3;302(7836):1027-8. doi: 10.1016/s0140-6736(73)91120-3.
PMID:4127250
Abstract
摘要
相似文献
1
Letter: Levodopa in dystonia.信件：左旋多巴治疗肌张力障碍。
Lancet. 1973 Nov 3;302(7836):1027-8. doi: 10.1016/s0140-6736(73)91120-3.
2
Levodopa-induced dystonia.左旋多巴诱发的肌张力障碍
Lancet. 1972 Dec 16;2(7790):1317-8. doi: 10.1016/s0140-6736(72)92694-3.
3
Levodopa in dystonia musculorum deformans.左旋多巴治疗变形性肌张力障碍
Lancet. 1973 Feb 24;1(7800):432. doi: 10.1016/s0140-6736(73)90296-1.
4
Levodopa in dystonia musculorum deformans.左旋多巴治疗变形性肌张力障碍
Lancet. 1973 May 19;1(7812):1114. doi: 10.1016/s0140-6736(73)90417-0.
5
[L-DOPA therapy of deforming muscular dystonia in children].[左旋多巴治疗儿童变形性肌营养不良症]
Zh Nevropatol Psikhiatr Im S S Korsakova. 1973;73(10):1495-8.
6
[Recessive dopa-responsive form of dystonia due to a mutation of the tyrosine hydroxylase gene].
Bull Acad Natl Med. 1999;183(3):639-46; discussion 646-7.
7
[Disulfiram and L-dopa in patients with Parkinson's syndrome and in torsion dystonia].
Prensa Med Mex. 1972 Jul-Aug;37(7):246-50.
8
[Diagnostic and therapeutic problems in dystonia musculorum deformans].[变形性肌张力障碍的诊断与治疗问题]
Riv Neurol. 1976 Jan-Feb;46(1):73-80.
9
Biochemical and pharmacologic studies of dystonia.肌张力障碍的生化与药理学研究。
Neurology. 1970 Nov;20(11):122-30. doi: 10.1212/wnl.20.11_part_2.122.
10
Dystonia musculorum deformans: implications of therapeutic response to levodopa and carbamazepine.变形性肌张力障碍：左旋多巴和卡马西平治疗反应的意义
Arch Neurol. 1982 Jun;39(6):376-7. doi: 10.1001/archneur.1982.00510180054014.
Zotero 插件